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Many patients with anti-Yta receive multiple transfusions of 
Yt(a+) red blood cells (RBCs) with no ill effects. However, anti-Yta 
has been implicated in hemolytic transfusion reactions. Antibody 
identification typically determines specificity of antibodies 
and their clinical significance to justify blood requirements for 
antigen-negative blood when clinically significant antibodies 
are involved. Occasionally, specificity of antibody is of variable 
significance. Variability in clinical significance is a characteristic 
of anti-Yta that may affect the clinical management of such 
patients. This case reports the outcome of an incompatible 
transfusion in an 83-year-old female patient with anti-Yta, -D, 
-C, -Leab, and -HI who was admitted to the hospital for a severe 
urinary tract hemorrhage and fever. The patient was transfused 
with 1 crossmatch-incompatible group A, Yt(a+), D–, C–, E–, 
S– RBC unit in an emergency medical event. During that 
time, the patient exhibited chills, shivering, and tachycardia. 
Decreases in hemoglobin and hematocrit were noted. Laboratory 
parameters for hemolysis, such as total bilirubin, direct bilirubin, 
and lactate dehydrogenase, were increased. Based on clinical 
and laboratory evaluation, it was concluded that the patient 
had an acute hemolytic transfusion reaction caused by anti-
Yta. The patient was successfully treated with antipyretics, 
antihistamines, and corticosteroids. Urinary tract hemorrhaging 
was stopped. Anemia was additionally improved with parenteral 
iron supplementation, and further transfusion was not required. 
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The Yta antigen is part of the Cartwright blood group 
system (YT). The YT system is the 11th human blood group 
system recognized by the International Society of Blood 
Transfusion (ISBT 011), which now includes five antigens: one 
pair of antithetical antigens, Yta and Ytb, and three additional 
high-prevalence antigens (HPAs): YTEG, YTLI, and YTOT.1 
YT antigens are found on the glycosylphosphatidylinositol-
linked red blood cell (RBC) glycoprotein acetylcholinesterase 
(AChE), which plays an essential part in neurotransmission.2 
The importance of AChE is further evidenced by the lack of 
any known inherited Yt(a–b–) phenotype. YT antigens are 
encoded by ACHE on chromosome 7q22.
Yta is an HPA found in all populations.3 It was first 
described in 1956 by Eaton et al.4 Later studies showed that 
approximately 1 in 500 individuals of European descent 
are Yt(a–).5,6 Individuals of Jewish descent and Middle 
Eastern ethnicities tend to have lower prevalence of Yt(a+).7 
The phenotype is less common in African Americans, with 
approximately 1 in 2000 Yt(a–) individuals.8 As a result, 
blood lacking Yta is very rare and should be preserved for its 
most appropriate use. Anti-Yta is categorized into a group of 
antibodies with variable clinical significance and unknown 
hemolytic potential. Therefore, it is of outmost importance 
to determine those patients who require rare Yt(a–) blood 
to avoid hemolytic transfusion reactions (HTRs). For this 
purpose, in vitro methods, such as RBC survival studies or 
cellular assays, the monocyte monolayer assay (MMA), and the 
chemiluminescence test (CLT), have been recommended.9–11
Several case reports describing anti-Yta in patients have 
demonstrated rapid in vivo destruction of Yt(a+) RBCs.12–14 
However, Dobbs et al.15 studied three patients with anti-Yta: 
two pregnant women without the evidence of hemolytic 
disease of the fetus and newborn (HDFN) and one patient 
with pure RBC aplasia and no HTR after transfusion of Yt(a+) 
RBCs. In this report, we describe a patient with an acute 
hemolytic transfusion reaction (AHTR) after the transfusion 
of 1 crossmatch-incompatible Yt(a+) RBC unit.
Case Report
In 2016, an 83-year-old white female patient of Croatian 
ancestry was admitted to the hospital with hematemesis from a 
duodenal ulcer. The patient’s hospital admission was attributed 
to poorly controlled anticoagulant therapy for the management 
of deep venous thrombosis, which previously led to cerebral 
infarction. Admission hemoglobin (Hb) was 6.6 g/dL and 
medication included only warfarin. According to the medical 
records history, the patient had a mixture of anti-D, anti-C, 
and a suspected additional antibody at an outside hospital 
in 2005, but antibody investigation was not completed. The 
patient had two pregnancies and no transfusions.
Initial evaluation in year 2016 confirmed anti-D and 
anti-C in the patient’s plasma. An antibody of unknown 
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specificity that was suspected in year 2005 in this patient 
was not detected. Initial panels for the antibody investigation 
included ID-DiaPanel and ID-Panel-P (Bio-Rad, Cressier, 
Switzerland), Panel C (Ortho Clinical Diagnostics, Raritan, 
NJ), and Identisera Diana, Identisera Diana P, Identisera 
Diana Extend, and Identisera Diana Extend P (Diagnostics 
Grifols, Barcelona, Spain). The patient’s blood group and 
RBC phenotype were reported as group A, C–D–E–; K+k+; 
Jk(a+b+); Fy(a+b+); M+N+S–s+; and P1+ by the conventional 
serology tube method.
The patient received 3 units of fresh frozen plasma (FFP), 
immediately followed by 1 unit of crossmatch-compatible 
group A, C–, D–, E–, S– RBCs. The following day, 2 units 
of crossmatch-compatible group A, C–, D–, E–, S– RBCs 
were transfused for an Hb of 6.9 g/dL. Although antibody 
investigation confirmed only anti-D and -C to be present in 
the patient’s plasma, RBCs units transfused were D–, C–, E–, 
and S–. RBC units negative for E and S were given because 
of the report from 2005 where another antibody specificity 
in addition to anti-D and -C was suspected in the patient’s 
plasma. Assuming this antibody could have been anti-S, and 
to avoid alloimmunization to E, RBC units transfused were 
also S– and E–.
Another RBC unit was requested 6 days later for an Hb 
of 9.3 g/dL. The crossmatch was weakly positive. Additional 
studies revealed the presence of anti-D and -C and an 
apparent alloantibody to the HPA. Findings of the serologic 
investigation were communicated to the clinic. Laboratory 
parameters were negative for hemolysis (total bilirubin [TB] 20 
µmol/L, normal values 3–20 µmol/L; lactate dehydrogenase 
[LDH] 217 U/L, normal values <241 U/L). Therefore, HTR 
was not suspected. Because the clinical condition of the patient 
was stable, the attending physician cancelled the transfusion 
request that was sent to further improve anemia. The next 
day, new samples were requested, but the patient had already 
been discharged from the hospital.
Obtaining new blood samples was coordinated by the 
patient’s caregivers. The patient was living in a nursing home, 
at which the nurses collected and arranged the transport of 
samples to the hospital. From the hematologic status at the 
nursing facility, the patient’s Hb was 12.7 g/dL.
A few weeks later, samples that had been collected 
while the individual was in outpatient care were received for 
antibody identification and sent to the International Reference 
Laboratory (IRL). In the plasma of the patient, the following 
complex mixture of antibodies was revealed: anti-Yta, -D, -C, 
-Leab, and -HI. A variety of methods, including alloadsorption-
elution studies and inhibition tests using soluble recombinant 
Yta proteins, were used. At the IRL, genomic DNA was isolated 
from the whole blood. Polymerase chain reaction amplification 
and Sanger sequencing of all coding exons of erythroid isoform 
of ACHE were carried out. The results showed that the patient 
had the YT*B genotype and, therefore, a Yt(a−b+)-predicted 
phenotype.
The patient was again hospitalized in 2019 for hematuria, 
caused by over-anticoagulation, and fever as a consequence 
of urinary tract infection. A total of 3 units of FFP were 
transfused, after which 2 RBC units were ordered from the 
emergency department for severe anemia (Hb 6.5 g/dL). 
Crossmatching and initial panels for antibody identification 
gave equally positive reactions (2+) with all RBCs tested 
by low-ionic-strength saline solution (LISS)–indirect 
antiglobulin test (IAT). Findings of the serologic testing and 
risks of anti-Yta associated with the incompatible transfusion 
were communicated to the clinic. Because of the rarity and 
complexity in obtaining Yt(a–) RBC units, the suggestion was 
made to cancel the RBC transfusion. Based on severe urinary 
tract hemorrhage, anemia, and the severely disturbed general 
condition of the patient, the attending physician decided to 
transfuse the patient with 1 crossmatch-incompatible RBC 
unit. In addition to the urinary tract hemorrhage and anemia, 
the patient had pneumonia, a urinary tract infection, and 
was febrile, dehydrated, somnolent, hypo-oxygenated, and 
hypotensive. 
Thirty minutes after premedication (which consisted of 80 
mg methylprednisolone and 1 ampoule of chloropyramine), 
the patient was transfused with 1 crossmatch-incompatible 
group A, C–, D–, E–, S– RBC unit. There was no possibility to 
do additional testing, or to search for a compatible or the least 
incompatible unit at the time because the blood transfusion 
was needed during night hours over the weekend. The 
transfusion was stopped after the patient had received 130 mL 
RBCs because she exhibited chills, shivering, and tachycardia, 
which were not present before transfusion. A sample was 
drawn immediately after the transfusion was stopped. Under 
the suspicion of an AHTR, the pre- and post-reaction samples 
were evaluated.
In the pre-transfusion antibody study, the crossmatch was 
incompatible with the selected group A, C–, D–, E–, S– RBC 
unit. A pre-transfusion direct antiglobulin test (DAT), using 
anti-IgG and anti-C3d, was negative. ID-Card LISS/Coombs 
cards with polyspecific antihuman globulin (rabbit anti-IgG 
and monoclonal anti-C3d, cell line C139-9) and DC-Screening 
II cards with monospecific anti-IgG and -C3d (Bio-Rad) were 
IMMUNOHEMATOLOGY, Volume 37, Number 1, 2021 15
AHTR caused by anti-Yta
used for the DAT. In evaluation studies, the patient’s plasma 
was adsorbed with three randomly selected C+, D+, E–, S– 
RBCs to remove anti-D, -C, and -Yta. The presence of new 
alloantibodies in the patient’s plasma was excluded by LISS-
IAT with untreated and papain-treated RBCs. The donor’s 
RBCs were retested with the patient’s adsorbed plasma to 
determine whether any additional antibodies existed apart 
from the anti-Yta. Negative results confirmed that no additional 
antibodies were present in the patient’s plasma, including 
antibodies to low-prevalence antigens. At the IRL, the patient’s 
plasma was tested with two examples of D–, C–, Le(a–b–), 
Yt(a–) untreated RBCs by LISS-IAT that were compatible, 
confirming anti-Yta in the patient’s plasma and excluding 
additional antibodies, such as antibodies to HPAs. Patient’s 
plasma was also tested with Yt(a–), Le(a+) RBCs to detect anti-
Lea; anti-Lea was not detected by the LISS-IAT. 
In the post-transfusion antibody study, the crossmatch was 
incompatible with the selected group A, C–, D–, E–, S– RBC 
unit. Post-transfusion DAT was positive: anti-IgG 1+; anti-
C3d negative. An acid eluate was performed using DiaCidel 
(Bio-Rad). Anti-Yta was found in the eluate, reacting moderate 
strength by LISS-IAT with untreated RBCs and marginally 
weaker with papain-treated RBCs. Post-transfusion eluate 
was tested additionally with Yt(a–), Le(a+) RBCs; anti-Lea was 
excluded. The eluate was then adsorbed to remove anti-Yta. No 
other additional antibodies were detected in the eluate. Also, 
no new antibodies were detected in the serum of the post-
transfusion sample after alloadsorption with three randomly 
selected C+, D+, E–, S– RBCs.
The results of the transfusion reaction evaluation are 
shown in Table 1. The following laboratory findings suggested 
an AHTR: decreased levels of Hb and hematocrit (Hct), and 
increased levels of TB, direct bilirubin, and LDH (Table 2). 
The patient was successfully treated with antipyretics, 
antihistamines, and corticosteroids. Over-anticoagulation was 
resolved, and urinary tract hemorrhaging ceased. Parenteral 
iron supplementation was implemented, the patient’s anemia 
was improved, and further transfusion was not required.
Discussion
An AHTR may occur when RBCs are transfused to 
a patient with a preexisting antibody that destroys the 
transfused incompatible RBCs. AHTR is characterized by a 
rapid destruction of RBCs immediately after transfusion.
Our patient was transfused during the night over the 
weekend in an emergency medical event with 1 crossmatch-
incompatible group A, Yt(a+), C–, D–, E–, S– RBC unit, 
because there was no time to obtain Yt(a–) blood or to 
search for the least incompatible RBC unit. All findings were 
consistent with AHTR. The patient suffered chills, shivering, 
and tachycardia. Laboratory parameters for hemolysis were 
positive including  decreases in Hb and Hct, as well as an 
increase in TB, direct bilirubin, and LDH. DAT was positive. 
At the time of admission, the patient had hematuria, and, as a 
result, hemoglobinuria could not be analyzed separately. In the 
post-transfusion eluate, anti-Yta was confirmed. No additional 
antibodies were detected. It is known that anti-HI can rarely 
cause delayed hemolysis mostly with group O RBCs, which is 
highly unlikely in this case, since the patient was transfused 
with group A RBCs. Lewis antibodies, particularly anti-Lea, 
seldom cause HTR if they are reactive at 37°C by the IAT.2 The 
risk of HTR is lower if Le(a+) RBCs of group A are transfused 
Table 1. Transfusion reaction evaluation
Laboratory evaluation Pre-transfusion Post-transfusion
ABO and D Group A, D– Group A, D–




Antibody detection test Positive Positive
Crossmatch with the 
transfused RBC unit
2+ 2+
DAT (anti-IgG) Negative 1+
RBC = red blood cell; DAT = direct antiglobulin test; Ig = immunoglobulin.











Hemoglobin (g/dL) 6.5 5.7 9.5 11.9–15.7 
Hematocrit (%) 20.9 18.8 28.8 35.6–47.0 
Reticulocytes (109/L) NT 113 139 22–97 
Total bilirubin 
(µmol/L)
20 46 16 3–20 
Direct bilirubin 
(µmol/L)
NT 14 NT <5 
Lactate 
dehydrogenase (U/L)
200 353 270 <241
Haptoglobin (g/L) NT 1.26 NT 0.30–2.20 
Urine analysis
Proteins 3+ Negative NT Negative
Urobilinogen 1+ Negative NT Negative
Erythrocytes 3+ 3+ NT Negative
NT = not tested. 
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since group A RBCs express fewer Lewis antigens than 
group O RBCs.16 In the case presented here, anti-Lea was not 
reactive at 37°C by the IAT and therefore was considered non-
significant. Group A RBCs were also transfused to the patient. 
Involvement of anti-Lea in the HTR was finally excluded by 
testing the post-transfusion eluate. From the transfusion 
reaction evaluation, we concluded that the transfusion reaction 
was caused by anti-Yta. All other possible causes for the 
AHTR, such as thermal destruction of RBCs and concomitant 
administration of drugs, were excluded, since the patient 
was not transfused through blood warmers, and she did not 
receive any drugs during the transfusion. Our patient did not 
receive further RBC units during hospitalization because her 
anemia improved when over-anticoagulation was resolved 
and urinary tract hemorrhaging ceased. Anemia was further 
improved with parenteral iron supplementation.
This case describes an instance of an AHTR caused 
by anti-Yta. Previous reports have described rapid in vivo 
destruction of Yt(a+) RBCs in patients with anti-Yta using the 
51chromium (51Cr) labeling survival study.12–14 A case study by 
Bettigole et al.12 documented the injection of a small volume 
of 51Cr-labeled Yt(a+) RBCs into a prostatic carcinoma patient 
with anti-Yta. The half-life of the transfused RBCs at 12 minutes 
was estimated to be 3 days. Anti-Yta was concluded to have 
the potential to cause an HTR.12 In the report by Göbel et al.,13 
shortened survival of injected 51Cr-labeled Yt(a+) RBCs was 
induced by anti-Yta in a mother immunized during her second 
pregnancy, but the anti-Yta did not cause HDFN. The third 
case reports anti-Yta with rapid destruction of injected 51Cr 
Yt(a+) RBCs. It was concluded that transfusion of Yt(a+) blood 
would result in an HTR.14 Although previous reports of anti-Yta 
suggested it to be a clinically significant antibody concerning 
transfusion, some patients with anti-Yta received Yt(a+) blood 
without apparent reaction.4,15 In the report by Eaton et al.,4 
anti-Yta was detected in the patient 4 days after a second series 
of transfusions. Although there was a weakly positive DAT 
60 days after transfusion, it was concluded that Yt(a+) RBCs 
were still present and that anti-Yta did not reduce the survival 
of transfused RBCs.4 Dobbs et al.15 studied one patient with 
pure RBC aplasia and no HTR after transfusion of Yt(a+) 
RBCs. This finding may be explained by the immunoglobin 
G (IgG) subclass composition of the anti-Yta cases, as an in 
vitro method used to assess the clinical significance of RBC 
antibodies. Reported examples of anti-Yta showed that it is 
almost always of the IgG class.17,18 According to these studies, 
the presence of IgG1 as well as IgG4 are characteristic of anti-
Yta.17,18 IgG subclass composition, especially the absence of 
IgG3, may explain the often-benign effects of anti-Yta. It is 
well known that IgG3 is thought to be the driving force behind 
AHTR. Therefore, severe reactions should be expected where 
IgG3 is implicated. IgG subclassing of our patient’s anti-Yta 
was not carried out because it was not available.
AuBuchon et al.19 demonstrated a change in clinical 
significance of anti-Yta. In that study, the ability of the patient’s 
anti-Yta to shorten the lifespan of 51Cr-labeled Yt(a+) RBCs 
increased almost threefold, 3 months after transfusion with 4 
units of Yt(a+) RBCs. The change occurred several years after 
the initial appearance of the anti-Yta, so this change would 
not be related to a progression in antibody class or subclass 
evolution as part of a primary antibody response. The change 
in clinical significance was due rather to the appearance of an 
IgG1 component of the anti-Yta, as a response to the further 
transfusion of RBCs to which the patient had been previously 
sensitized. Mohandas et al.20 suggested considerable variability 
in the tolerance of Yt(a+) transfusions of patients with anti-Yta. 
Based on their experience, transfusion of Yt(a+) RBCs into 
patients with anti-Yta is likely to be safe, more often than not. 
Nevertheless, patients with anti-Yta should not be transfused 
routinely with Yt(a+) RBCs. Antibodies to Yta have not caused 
HDFN, despite several cases of women with anti-Yta identified 
after having Yt(a+) children. This finding may be partly 
explained due to weak expression of Yta on fetal RBCs.21,22
Because anti-Yta has shown variable significance in 
the literature, cellular assays can be performed to ascertain 
the clinical significance of anti-Yta. The MMA measures the 
adherence and phagocytosis of sensitized RBCs by human 
monocytes, which is determined microscopically. The CLT 
measures the metabolic bioproducts associated with the 
phagocytosis of sensitized RBCs using luminol to produce 
light. MMA is found to be a reliable predictor of the clinical 
significance of anti-Yta.10,23 Eckrich et al.23 conducted a 
retrospective review of MMA results on sera from 79 patients 
with anti-Yta. They found that MMA is a reliable predictor of 
the clinical significance of anti-Yta, when samples for analysis 
were collected at least 6 weeks after initial detection of the 
antibody.23 Results using the CLT suggested that it might be 
used in a similar manner to the MMA, to predict an outcome of 
transfusing incompatible blood.11 According to Hadley et al.,11 
results from MMA and CLT are in good agreement, although 
some sera were strongly reactive in the MMA and weakly 
reactive in the CLT. Sera that promote RBC adherence more 
than phagocytosis may be more reactive in the MMA.11 MMA 
is available in several laboratories to predict the survival of 
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transfused incompatible RBCs, but it is currently not available 
in Croatia.
In conclusion, for transfusion purposes, cellular assays, 
such as MMA or CLT, should be performed when time permits 
to determine the clinical significance of anti-Yta. Based on 
these results, rare Yt(a–) blood units should be obtained only 
for the patients with clinically significant anti-Yta. Because IgG 
subclass may be related to clinical significance of anti-Yta, IgG 
subclassing is recommended when possible.
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